Blood Borne Diseases Screening Articles & Analysis
10 news found
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic Integration Will Simplify the Process for Clinicians to Order Tests and Access Results Directly in the Patient Record REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the ...
Lawsuit is Seen as an Attempt to Stifle Competition and Retaliate Against Guardant Health for Registering Concerns About the Antitrust Implications of Illumina’s Acquisition of Grail REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks to ...
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding. The funding is from five private investors including Dr. Jacque Sokolov, a Calviri Board member, and Dr. Mitzi Krockover. Calviri was founded based on the discovery that tumors make frequent and ...
ByCalviri
Grifols has adopted several measures aimed at reinforcing its strong commitment to its main stakeholders in regards to the new situation posed by the coronavirus (COVID-19) outbreak. At Grifols, we believe this current and extraordinary situation requires companies to strive more than ever to serve patients and society in a responsible manner. A clear responsibility to donors and patients ...
The U.S. Environmental Protection Agency (EPA) and its partners in Oklahoma are celebrating a significant achievement in children’s health: Since 1997, blood lead levels of children in Ottawa County and Tar Creek have drastically declined, with 0% of children in these areas showing elevated levels by 2013. “The children of Tar Creek and Ottawa County are healthier today because of ...
The International Conference on Alzheimer"s disease in Hawaii heard that scientists from the Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) have identified advances in imaging and blood screening that will contribute to the earlier detection of Alzheimer’s. About 250,000 Australians currently have Alzheimer’s disease, but numbers are anticipated to rise ...
Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug." ...